摘要
本文应用１３１Ｉ标记的抗人结肠癌单克隆抗体（ｍＡｂ）Ｓｃ３Ａ及其Ｆ（ａｂ′）２作为导向治疗剂，加ｒＨｕＩＦＮ－γ治疗荷人结肠癌裸鼠获得明显的抑瘤效果。结果表明，ｒＨｕＩＦＮ－γ＋１３１Ｉ－Ｓｃ３ＡｍＡｂ或１３１Ｉ－Ｆ（ａｂ′）２的抑瘤作用分别为８４．５％和９１．９％，明显优于ＰＢＳ＋１３１Ｉ－Ｓｃ３ＡｍＡｂ或１３１Ｉ－Ｆ（ａｂ′）２治疗组（分别为６９．６％或６０．５％）；Ｆ（ａｂ′）２组优于完整的ｍＡｂ组，提示ＩＦＮ－γ具有良好的导向辅佐作用。上述结果可为临床应用提供重要的实验依据。
In the present study, we found that rHuIFN γ can enhance the localization of 131 I radiolabelled mAb Sc3A in human colon carcinoma xenografts of athymic mice as well as the effect of radioimmunotherapy. The tumor inhibitory rates of 131 I Sc3A F(ab′) 2 plus rHuIFN γ and 131 I Sc3A plus rHuIFN γ were 91.9% and 84.4%, respectively. While those of PBS plus 131 I Sc3A F(ab′) 2 and PBS plus 131 I Sc3A groups were 69.6% and 60.5%, respectively. In addition, the xenograft tumors in the specific mAb groups began to degenerate on day 5 after first injection of 131 I labelled mAb plus IFN γ. The tumor volume of the animals receiving 131 I Sc3A plus rHuIFN γ accounted for 19.4% of that of the animals receiving rHuIFN γ alone. While the tumor volumes of the animals receiving 131 I Sc3A F(ab′) 2 or 131 I Sc3A plus PBS accounted for 39.5% and 30.4% of that of the animals receiving PBS alone, respectively. These results indicated that rHuIFN γ could augment the curative effect of 131 I labelled specific mAbs in tumor targeting therapy.
出处
《细胞与分子免疫学杂志》
CAS
CSCD
1998年第4期265-267,261,共4页
Chinese Journal of Cellular and Molecular Immunology
